Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Solid Tumors 2Lung Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Histologically or Cytologically Documented Solid Tumors 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × motesanib diphosphate × Clear all
NCT00101907 2014-03-20

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Amgen

Phase 1 Terminated
41 enrolled 17 charts
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡